Logotipo del repositorio
 

Triple combination of insulin glargine, sitagliptin and metformin in type 2 diabetes : the EASIE post-hoc analysis and extension trial

Vista sencilla de ítem
dc.contributor.authorChan, Juliana C.N.
dc.contributor.authorAschner Montoya, Pablo
dc.contributor.authorOwens, David R.
dc.contributor.authorPicard, Sylvie
dc.contributor.authorVincent, Maya
dc.contributor.authorDain, Marie Paule
dc.contributor.authorPilorget, Valerie
dc.contributor.authorLoizeau, Virginie
dc.contributor.authorEchtay, Akram
dc.contributor.authorFonseca, Vivian
dc.contributor.corporatenamePontificia Universidad Javeriana. Facultad de Medicina. Departamento de Endocrinología
dc.date.accessioned2021-02-18T02:51:26Z
dc.date.available2021-02-18T02:51:26Z
dc.date.created2015
dc.description.abstractenglishAim We examined the effects of adding glargine to metformin–sitagliptin (MS + G) or sitagliptin to metformin–glargine (MG + S) therapy in type 2 diabetic persons uncontrolled after 24-week MS or MG dual therapy. Methods Subjects with A1c ≥ 7% on MS or MG treatment were respectively given glargine (0.2 U/kg starting dose) or sitagliptin (100 mg daily) for 12 weeks. The primary endpoint was number of subjects attaining A1c goal defined as < 7%. Results After receiving 24-week MS or MG dual therapy in the original EASIE Study, 42% (104/248) on MS and 68% (152/224) on MG attained A1c < 7% (p < 0.0001). The reduction in A1c was negatively associated with baseline fasting blood glucose (FBG) only in the MG group. Reduction in A1c was not related to baseline postprandial blood glucose (PPBG) in either the MG or MS group. Amongst 194 eligible patients, 57.7% (n = 111) entered the 12-week extension trial [MS + G:74/131, 57.3%; MG + S:37/63, 58.7%) with 55 (51.9%) subjects attaining goal [MS + G:59.2%; MG + S:37.1%] at week 12. The final insulin dosage was similar in both groups [MS + G: 0.46 U/kg; MG + S: 0.45 U/kg] with a higher rate of hypoglycemia in the MG + S (6.5 events/patient-year) than the MS + G group (3.2 events/patient-year), although neither group had severe hypoglycemia. Conclusion In metformin-treated type 2 diabetes patients, high fasting BG predicted greater A1c reductions with the addition of glargine, but not with sitagliptin. In subjects uncontrolled with 6-month dual therapy of MS or MG, 50% attained A1c < 7% with triple therapy of MS + G or MG + S in 12 weeks. The increased rate of hypoglycemia with MG + S (but not with MS + G) underlines the need to take measures to avoid the hypoglycemia.spa
dc.description.quartilescopusQ1spa
dc.description.quartilewosQ3spa
dc.formatPDFspa
dc.format.mimetypeapplication/pdfspa
dc.identifierhttps://www.sciencedirect.com/science/article/pii/S1056872714002530#!spa
dc.identifier.doihttps://doi.org/10.1016/j.jdiacomp.2014.08.007spa
dc.identifier.instnameinstname:Pontificia Universidad Javerianaspa
dc.identifier.issn1056-8727 / 1873-460X (Electrónico)spa
dc.identifier.reponamereponame:Repositorio Institucional - Pontificia Universidad Javerianaspa
dc.identifier.repourlrepourl:https://repository.javeriana.edu.cospa
dc.identifier.urihttp://hdl.handle.net/10554/53013
dc.language.isoengspa
dc.relation.citationendpage141spa
dc.relation.citationissue1spa
dc.relation.citationstartpage134spa
dc.relation.citationvolume29spa
dc.relation.ispartofjournalJournal of Diabetes and Its Complicationsspa
dc.rights.coarhttp://purl.org/coar/access_right/c_abf2spa
dc.rights.licenceAtribución-NoComercial 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/*
dc.subject.keywordEASIEspa
dc.subject.keywordA1cspa
dc.subject.keywordInsulin glarginespa
dc.subject.keywordMetforminspa
dc.subject.keywordSitagliptinspa
dc.subject.keywordType 2 diabetesspa
dc.titleTriple combination of insulin glargine, sitagliptin and metformin in type 2 diabetes : the EASIE post-hoc analysis and extension trialspa
dc.type.coarhttp://purl.org/coar/resource_type/c_6501spa
dc.type.hasversionhttp://purl.org/coar/version/c_ab4af688f83e57aa
dc.type.localArtículo de revistaspa

Archivos

Bloque original
Mostrando 1 - 1 de 1
Miniatura
Nombre:
Triple combination of insulin glargine, sitagliptin and metformin intype 2 diabetes.pdf
Tamaño:
655.37 KB
Formato:
Adobe Portable Document Format
Descripción:
Artículo
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
2.54 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Artículos